APLT Quote, Financials, Valuation and Earnings

Cellectar Biosciences has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Cellectar Biosciences's return on equity of --.

Applied Therapeutics has a consensus price target of $6.80, signalling upside risk potential of 594.77%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 2135.37%. Given that Cellectar Biosciences has higher upside potential than Applied Therapeutics, analysts believe Cellectar Biosciences is more attractive than Applied Therapeutics.

Applied Therapeutics has a beta of 1.765, which suggesting that the stock is 76.451% more volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.942%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are larger than Cellectar Biosciences quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Cellectar Biosciences's net income of -$14.7M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 657.46x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -104.98%. Applied Therapeutics's return on equity of -797.82% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Applied Therapeutics has a consensus price target of $6.80, signalling upside risk potential of 594.77%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 67.97%. Given that Applied Therapeutics has higher upside potential than Ionis Pharmaceuticals, analysts believe Applied Therapeutics is more attractive than Ionis Pharmaceuticals.

Applied Therapeutics has a beta of 1.765, which suggesting that the stock is 76.451% more volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Applied Therapeutics's net income of -$68.6M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 6.64x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Cassava Sciences's return on equity of --.

Applied Therapeutics has a consensus price target of $6.80, signalling upside risk potential of 594.77%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4857.27%. Given that Cassava Sciences has higher upside potential than Applied Therapeutics, analysts believe Cassava Sciences is more attractive than Applied Therapeutics.

Applied Therapeutics has a beta of 1.765, which suggesting that the stock is 76.451% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are larger than Cassava Sciences quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Cassava Sciences's net income of -$27.9M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 2.57x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -82.56%. Applied Therapeutics's return on equity of -797.82% beat Verastem's return on equity of -120.71%.

Applied Therapeutics has a consensus price target of $6.80, signalling upside risk potential of 594.77%. On the other hand Verastem has an analysts' consensus of -- which suggests that it could grow by 185.26%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

Applied Therapeutics has a beta of 1.765, which suggesting that the stock is 76.451% more volatile than S&P 500. In comparison Verastem has a beta of 0.221, suggesting its less volatile than the S&P 500 by 77.906%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are smaller than Verastem quarterly revenues of $10M. Applied Therapeutics's net income of -$68.6M is lower than Verastem's net income of -$24M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.